Valneva SE Sponsored ADR (NASDAQ:VALN) Given Consensus Rating of “Hold” by Brokerages

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have been assigned a consensus rating of “Hold” from the four analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $9.30.

Several research firms have commented on VALN. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research note on Monday, June 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valneva in a research note on Thursday, June 18th. Finally, TD Cowen began coverage on Valneva in a research report on Tuesday, August 11th. They set a “buy” rating and a $12.00 price target for the company.

Institutional Investors Weigh In On Valneva

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Valneva during the fourth quarter worth $44,000. JPMorgan Chase & Co. purchased a new position in shares of Valneva in the third quarter worth about $124,000. XTX Topco Ltd purchased a new position in shares of Valneva in the fourth quarter worth about $94,000. Finally, Marex Group plc acquired a new stake in Valneva in the 2nd quarter valued at about $64,000. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Stock Down 3.0%

Shares of NASDAQ VALN opened at $6.75 on Tuesday. The firm has a market cap of $640.51 million, a price-to-earnings ratio of -3.20 and a beta of 1.77. The company’s 50-day simple moving average is $5.43 and its 200-day simple moving average is $6.80. The company has a quick ratio of 1.69, a current ratio of 2.16 and a debt-to-equity ratio of 2.04. Valneva has a 52-week low of $4.75 and a 52-week high of $12.23.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.21). The company had revenue of $39.37 million for the quarter, compared to analyst estimates of $44.17 million. Valneva had a negative return on equity of 153.20% and a negative net margin of 110.33%. Equities analysts predict that Valneva will post -1.27 EPS for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.